Monday, 30 May 2016

Usage in Companion Diagnostic Services Stimulates Global Transcriptomics Market to Reach US$4.6 Billion by 2019

Transparency Market Research, a global market intelligence consultancy, has published a market study on the global transcriptomics technologies market for the 2013-2019 period. According to this report, the global transcriptomics technologies market will rise at a CAGR of 15.90% from 2013 to 2019 to reach a valuation of US$4.6 bn by the end of the forecast period. The market’s valuation in 2012 was US$1.65 bn. The report is titled “Transcriptomics Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”.

Get Free Sample Research Report:
The report says that the global transcriptomics technologies market will witness substantial growth in the coming years due to several reasons. Transcriptomics research involves studying the structure and function of RNA present in a cell.Presently, transcriptome analysis of several organisms is assisted using next-generation sequencing platforms in the preliminary phase followed by polymerase chain reactions, gene regulation technologies, and microarrays in the latter part. The coalition of these technologies is used for drug discovery, clinical diagnosis of diseases, medical research, and others. With the ever-increasing demand for targeted therapeutics and continual improvement of healthcare infrastructure, the commercial usage of transcriptomics technologies holds promise. Transcriptomics research allows the development of newer therapeutics and diagnostics and further advancement of the existing line of treatment for medical conditions.

The report says that in the transcriptomics technologies market, the key application segments undergo consistent development in order to offer added value to users. For instance, the utilization of transcriptomics technologies has benefitted the pharmaceutical and biotechnology fields; other fields are also deriving the advantages of this technology for mutual benefits of both the technology and the application field. Laboratories attempting to use biomarkers and newer gene sequencing methods is an example of this.

The need for the development of adequate equipment in healthcare organizations and laboratories, the growing awareness about transcriptomics technologies globally, and increased participation of government bodies in transcriptomics research are some other factors driving this global market.

However, growth of the transcriptomics technologies market is hampered due to certain factors cited in this report. These include the unavailability of advanced equipment needed for biological computation, unavailability of services essential to analyzing complex information, and an overall deficit of technicians that have expertise in the subject.

The report divides the global transcriptomics technologies market into the regional segments of North America, Asia Pacific, Europe, and Rest of the World. Among the regional segments, Asia Pacific will exhibit a substantial uptake of these technologies and the fastest growth rate in the transcriptomics technologies market during the forecast period. Ongoing infrastructural development for improved healthcare and increased acceptance of novel biotechnology research are the reasons for this.

In 2012, North America led the global transcriptomics technologies market, contributing more than 35% of the revenue in the global market. The presence of advanced healthcare infrastructure, which includes well-equipped research facilities, increased awareness of biotechnology research, and the high number of initiatives taken by governments to promote research activities are the reasons for the dominant position of North America in this market.

The report mentions the top players that operate in the global transcriptomics market. These are Life Technologies Corporation, F-Hoffmann La Roche Ltd., Thermo Fisher Scientific, Illumina Inc., Agilent Technologies, and Affymetrix Inc.

Full Research Report on Global Transcriptomics Technologies Market:

Wednesday, 25 May 2016

Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market

Respiratory disease is a medical condition that includes pathological conditions that affect tissues and organs which assist in making gas exchange possible in the organisms. Respiratory disease ranges from self-limiting and mild, such as the common cold, to life-threatening conditions such as lung cancer, pulmonary embolism and bacterial pneumonia. Various respiratory disease conditions include disorder of upper respiratory tract, bronchi, bronchioles, trachea, pleura and pleural cavity, alveoli, and the nerves and muscles of breathing.

Upper respiratory tract disorder or infection (URI or URTI) is a medical condition caused by acute infection that involves upper respiratory tract such as sinuses, nose, larynx or pharynx. Pharyngitis, tonsillitis, sinusitis, laryngitis, common cold, and otitis media are some of the most common upper respiratory tract disorders. Upper respiratory tract disorders are caused by direct invasion of the mucus membrane (inner respiratory tract lining) by bacteria or virus. Rhinorrhea, sneezing, nasal congestion, nasal discharge, sore throat, cough, fever, odynophagia and malaise are some of the most common symptoms observed in the patient diagnosed with upper respiratory tract disorder. Some other symptoms of the disease are headache, foul breath, hyposmia, sinus pain, shortness of breath, conjunctivitis, vomiting diarrhea, nausea, and body ache.

Upper respiratory tract disorder can be diagnosed by physical examination, laboratory tests and review of symptoms. In physical examination, physicians look for redness and swollen inside the wall of nasal cavity, white secretions on the tonsils, redness of the eyes, redness of the throat, and enlarged lymph nodes around neck and head. Laboratory testing is usually not performed for examining upper respiratory tract disorders as most of the upper respiratory tract infections are caused by viruses and no specific treatment for different types of viral upper respiratory tract disorder is available in current scenario. Some of the laboratory tests that are performed for diagnosing upper respiratory tract disorder include imaging tests (X-ray and CT scan), blood tests and sputum tests.

Upper respiratory tract disorders can be treated with antibiotics and decongestants. Acetaminophen, ibuprofen, diphenhydramine, dextromethorphan, codeine, guaifenesin, dexamethasone and prednisone are some of the antibiotics that are prescribed to the patients suffering from upper respiratory tract disorders. Oxymetazoline, phenylephrine and pseudoephedrine are some of the most commonly prescribed decongestants for the treatment of upper respiratory tract disorders. Antibiotics are rarely used as a treatment option for upper respiratory tract disorders as they are associated with many side effects and also can initiate secondary infections and bacterial resistance.

The market for upper respiratory tract disorder diagnostics and therapeutics is expected to grow at a significant CAGR during the forecast period from 2014 to 2020 owing to increasing incidences of respiratory disorders across the globe. Similarly, constant changing climate condition due to global warming and pollution has further accentuated the risk for developing upper respiratory tract disorders. This in turn is expected to drive the growth of upper respiratory tract disorder diagnostics and therapeutics market. Currently, North America accounts for the largest share of the global upper respiratory tract disorder diagnostics and therapeutics market. This is due to the fact that the U.S. has witnessed for large patient pool suffering from upper respiratory tract disorders. 
Some of the major players operating in upper respiratory tract disorder diagnostics and therapeutics market include Alcon, Inc., Merck & Co., Inc., Collegium Pharmaceutical, Inc., GlaxoSmithKline plc and Verona Pharma Plc among other significant players across the globe.

Full Research Report on Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market:

Tuesday, 24 May 2016

M2M Connected Healthcare Market: Global Industry Trends and Forecast 2014 - 2020

Over the past few years, the healthcare industry has been witnessing increasing adoption of machine to machine (M2M) technology in order to reduce skyrocketing healthcare costs,   increase adherence to medical regimens and improve better patient care. M2M connected healthcare is a healthcare delivery model that operates in an IT ecosystem, and allow easy access and sharing of healthcare related data such as patient medical history data, patient personal information, prescription information, diagnostic results, clinical data and others. Home monitoring, clinical monitoring, assisted living and telemedicine are among the major functions carried out by M2M connected healthcare systems. M2M connected healthcare saves time by connecting patients, healthcare providers and treatment systems over the internet. The M2M connected healthcare systems can use wired or wireless connectivity to share healthcare data between web-connected devices without the need of human involvement.

The global market for M2M connected healthcare has been segmented into home monitoring, clinical monitoring, clinical trials, telemedicine, assisted living, worried well and clinical remote monitoring. Significant advantages associated with M2M connected healthcare have been identified as the major factors driving the M2M connected healthcare market growth. These advantages include reduced time, reduced healthcare cost, easy sharing of healthcare data and remote healthcare monitoring. M2M model also enables patients with more control over their treatment regime. Globally rising incidences of various chronic diseases such as diabetes, cancer and hypertension are also expected to play a key role in driving the market growth during the forecast period from 2014 to 2020. Persistent rise in geriatric population directly impacts the growth and development of connected health M2M services as elderly population is highly susceptible to acquire several health disorders as compared to younger adults. According to World Health Organization (WHO) projections, in 2010, global geriatric population was around 524 million and is anticipated to reach around 1.5 billion by the year 2050. Thus, a consistent rise in geriatric population would boost the growth of M2M connected healthcare market as they will increasingly seek M2M connected health services. One of the major factors that are expected to affect the market growth is that stake holders should have access to internet connection.

In terms of geography, the global market for M2M connected healthcare has been segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). North America represented the largest regional market for M2M connected healthcare in 2013. Well established healthcare infrastructure of the North American countries U.S. and Canada, and presence of a large pool of technically-savvy patient population are among the major factors responsible for North America’s leading position in this market segment. Europe represented the second largest market after North America. Germany, France, United Kingdom, Italy and Spain are the most potential markets in the European region that accounted for more than 60% of the overall Europe M2M connected healthcare market. During the forecast period from 2014 to 2020, APAC is expected to witness significant growth as M2M connected healthcare model will help in serving patients residing in remote area, overcoming distance barriers.

Allscripts, IBM, Apple, AirStrip Technologies, Cisco Networks, Microsoft, AT&T, BL Healthcare, Ingenious Med, NeuroVigil, PharmaSecure, QxMD Software, WellDoc and ObTech Medical are among the major players operating in this market. These players are competing with each other in order to get competitive advantages over others.

Full Research Report on Global M2M Connected Healthcare Market: